Company intelligence / Profile preview

ChosenMed Technology

Beijing, Beijing Municipality, Chinachosenmedtech.com ↗

Ownership: Private
Development stage: Other

Overview

ChosenMed has conducted large-scale genomic studies such as the Cancer Genome Atlas of China:Lung Cancer project involving 2,500 samples from 40 clinical centers to enable molecular typing of lung cancer using high-throughput sequencing. This supports new drug R&D and treatment guidance. The company’s platforms are used for early tumor screening, dynamic monitoring, medication guidance, prognostic evaluation, and bioinformatics analysis in clinical settings

Therapeutic areas: Oncology
Modalities: NGS-based diagnostics (Next-generation sequencing)Bioinformatics analysis
Industry: Molecular Diagnostics

Partnerships

Collaborations with Xuanwu Hospital Capital Medical University on national genomics projects; further academic collaborations likely but not explicitly listed.

Beyond the preview

Go deeper on ChosenMed Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChosenMed Technology.

Explore the full profile